NVAX vs VIR: stock comparison and AI forecast
Novavax Inc (NVAX) and Vir Biotechnology, Inc. (VIR) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
NVAX Novavax Inc
- Market Cap
- $1.61B
- P/E Ratio
- 108.7x
- Size
- small-cap
- AI Forecast
VIR Vir Biotechnology, Inc.
- Price
- $11.02 +7.1% · 6M
- Market Cap
- $1.86B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- VIR is 1.2 times larger than NVAX by market capitalization ($1.86B against $1.61B).
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | NVAX | VIR |
|---|---|---|
| Market Cap | $1.61B | $1.86B |
| P/E Ratio | 108.66x | – |
| P/B Ratio | – | 2.08x |
| EPS | $0.09 | $-1.76 |
| Book Value/Share | – | $5.30 |
| Revenue/Share | $2.50 | – |
| FCF/Share | – | $-0.84 |
Profitability & Margins
| Metric | NVAX | VIR |
|---|---|---|
| ROE | – | -20.6% |
| ROA | – | -16.6% |
| ROIC | -15.7% | -20.5% |
| Gross Margin | 78.0% | 50.7% |
| Operating Margin | -21.2% | -34.9% |
| Net Margin | – | -30.5% |
| EBT Margin | -17.5% | -30.5% |
| Tax Rate | -6.7% | -0.0% |
Financial Health
| Metric | NVAX | VIR |
|---|---|---|
| Current Ratio | 2.15x | 6.30x |
| Quick Ratio | 2.09x | – |
| D/E Ratio | – | 0.24x |
| Financial Leverage | – | 1.24x |
| Interest Coverage | -6.8x | – |
| Working Capital | $378M | $428M |
Cash Flow
| Metric | NVAX | VIR |
|---|---|---|
| Operating Cash Flow | -$239M | -$141M |
| Free Cash Flow | – | -$142M |
| Capital Spending | – | -$800K |
Operational Efficiency
| Metric | NVAX | VIR |
|---|---|---|
| Asset Turnover | 0.46x | – |
| Receivables Turnover | 8.4x | – |
| Inventory Turnover | 4.9x | – |
| Fixed Assets Turnover | 11.3x | – |
| Days Sales Outstanding | 44 days | – |
| Days Inventory | 75 days | – |
| Payables Period | 101 days | 158972 days |
| Cash Conversion Cycle | 18 days | – |
Income Statement
| Metric | NVAX | VIR |
|---|---|---|
| Total Revenue | $412M | – |
| Operating Income | -$87M | -$211M |
| Net Income | – | -$185M |
| R&D Expense | $294M | $413M |
| SG&A Expense | $205M | $102M |
| Cost of Goods Sold | $91M | $30K |
Dividend & Shareholder Information
| Metric | NVAX | VIR |
|---|---|---|
| Shares Outstanding | 165M | 169M |
| EPS Growth | -95.1% | – |
NVAX vs VIR: stock comparison and AI forecast
Which is bigger, NVAX or VIR?
VIR is 1.2 times larger than NVAX by market capitalization ($1.86B against $1.61B).
Which one does Intratio's AI model rank higher, NVAX or VIR?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.